四ノ宮成祥の業績一覧

・論文（2006年～）

  1. A. Nakayama, M. Nakatochi, Y. Kawamura, K. Yamamoto, H. Nakaoka, S. Shimizu, T. Higashino, T. Koyama, A. Hishida, K. Kuriki, M. Watanabe, T. Shimizu, K. Ooyama, H. Ooyama, M. Nagase, Y. Hidaka, D. Matsui, T. Tamura, T. Nishiyama, C. Shimanoe, S. Katsuura-Kamano, N. Takashima, Y. Shirai, M. Kawaguchi, M. Takao, R. Sugiyama, Y. Takada, T. Nakamura, H. Nakashima, M. Tsunoda, I. Danjoh, A. Hozawa, K. Hosomichi, Y. Toyoda, Y. Kubota, T. Takada, H. Suzuki, Blanka Stiburkova, T. J. Major, T. R. Merriman, N. Kuriyama, H. Mikami, T. Takezaki, K. Matsuo, S. Suzuki, T. Hosoya, Y. Kamatani, M. Kubo, K. Ichida, K. Wakai, I. Inoue, Y. Okada, N. Shinomiya, H. Matsuo on behalf of Japan Gout Genomics Consortium (Japan Gout). Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients. Ann. Rheum. Dis. (2020) (epub ahead of print on Apr. 1, 2020).

  2. A. Akashi, A. Nakayama, Y. Kamatani, T. Higashino, S. Shimizu, Y. Kawamura, M. Imoto, M. Naito, A. Hishida, M. Kawaguchi, M. Takao, M. Matsuo, T. Takada, K. Ichida, H. Ooyama, N. Shinomiya, H. Matsuo, A common variant of LDL receptor related protein 2 (LRP2) gene is associated with gout susceptibility: a meta-analysis in a Japanese population. Hum Cell 33, 303-307 (2020).

  3. T. Higashino, K. Morimoto, H. Nakaoka, Y. Toyoda, Y. Kawamura, S. Shimizu, T. Nakamura, K. Hosomichi, A. Nakayama, K. Ooyama, H. Ooyama, T. Shimizu, M. Ueno, T. Ito, T. Tamura, M. Naito, H. Nakashima, M. Kawaguchi, M. Takao, Y. Kawai, N. Osada, K. Ichida, K. Yamamoto, H. Suzuki, N. Shinomiya, I. Inoue, T. Takada, H. Matsuo, Dysfunctional missense variant of OAT10/SLC22A13 decreases gout risk and serum uric acid levels. Ann. Rheum. Dis. 79, 164-166 (2020) (epub ahead of print on Nov 28, 2019.).

  4. A. Nakayama, H. Matsuo, A. Ohtahara, K. Ogino, M. Hakoda, T. Hamada, M. Hosoyamada, S. Yamaguchi, I. Hisatome, K. Ichida, N. Shinomiya, Clinical practice guideline for renal hypouricemia (1st edition). Hum Cell 32, 83-87 (2019).

  5. Y. Kawamura, H. Nakaoka, A. Nakayama, Y. Okada, K. Yamamoto, T. Higashino, M. Sakiyama, T. Shimizu, H. Ooyama, K. Ooyama, M. Nagase, Y. Hidaka, Y. Shirahama, K. Hosomichi, Y. Nishida, I. Shimoshikiryo, A. Hishida, S. Katsuura-Kamano, S. Shimizu, M. Kawaguchi, H. Uemura, R. Ibusuki, M. Hara, M. Naito, M. Takao, M. Nakajima, S. Iwasawa, H. Nakashima, K. Ohnaka, T. Nakamura, B. Stiburkova, T. R. Merriman, M. Nakatochi, S. Ichihara, M. Yokota, T. Takada, T. Saitoh, Y. Kamatani, A. Takahashi, K. Arisawa, T. Takezaki, K. Tanaka, K. Wakai, M. Kubo, T. Hosoya, K. Ichida, I. Inoue, N. Shinomiya, H. Matsuo. Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout. Ann. Rheum. Dis. 78, 1430-1437 (2019) (epub ahead of print on Jul. 8, 2019).

  6. M. Nakatochi, M. Kanai, A. Nakayama, A. Hishida, Y. Kawamura, S. Ichihara, M. Akiyama, H. Ikezaki, N. Furusyo, S. Shimizu, K. Yamamoto, M. Hirata, R. Okada, S. Kawai, M. Kawaguchi, Y. Nishida, C. Shimanoe, R. Ibusuki, T. Takezaki, M. Nakajima, M. Takao, E. Ozaki, D. Matsui, T. Nishiyama, S. Suzuki, N. Takashima, Y. Kita, K. Endoh, K. Kuriki, H. Uemura, K. Arisawa, I. Oze, K. Matsuo, Y. Nakamura, H. Mikami, T. Tamura, H. Nakashima, T. Nakamura, N. Kato, K. Matsuda, Y. Murakami, T. Matsubara, M. Naito, M. Kubo, Y. Kamatani, N. Shinomiya, M. Yokota, K. Wakai, Y. Okada, H. Matsuo. Genome-wide meta-analysis identifies multiple novel loci associated with serum uric acid levels in Japanese individuals. Commun. Biol. 2. 115 (2019).

  7. M. Sakiyama, H. Matsuo, A. Akashi, S. Shimizu, T. Higashino, M. Kawaguchi, A. Nakayama, M. Naito, S. Kawai, H. Nakashima, Y. Sakurai, K. Ichida, T. Shimizu, H. Ooyama, N. Shinomiya. Independent effects of ADH1B and ALDH2 common dysfunctional variants on gout. Sci Rep. 7. 2500 (2017).

  8. H. Matsuo, T. Tsunoda, K. Ooyama, M. Sakiyama, T. Sogo, T. Takada, A. Nakashima, A. Nakayama, M. Kawaguchi, T. Higashino, K. Wakai , H. Ooyama, R. Hokari, H. Suzuki, K. Ichida, A.Inui, S. Fujimori, N. Shinomiya.　Hyperuricemia in acute gastroenteritis is caused by decreased urate excretion via ABCG2.　Sci. Rep. 6, 31003 (2016).

  9. M. Sakiyama, H. Matsuo, H. Nakaoka, K. Yamamoto, A. Nakayama, T. Nakamura, S. Kawai, R. Okada, H. Ooyama, T. Shimizu, N. Shinomiya. Identification of rs671, a common variant of ALDH2, as a gout susceptibility locus. Sci. Rep. 6, 25360 (2016).

  10. M. Sakiyama, H. Mastuo, S. Shimizu, H. Nakashima, T. Nakamura, A. Nakayama, T. Higashino, M. Naito, S. Suma, A. Hishida, T. Satoh, Y. Skurai, T. Takada, K. Ichida, H. Ooyama, T. Shimizu, N. Shinomiya, The effects of URAT1/SLC22A12 nonfunctional variants, R90H and W258X, on serum uric acid levels and gout/hyperuricemia progression. Sci. Rep. 6, 20148 (2016).

  11. Y. Honkura, H. Matsuo, S. Murakami, M. Sakiyama, K. Mizutari, A. Shiotani, M. Yamamoto, I. Morita, N. Shinomiya, T. Kawase, Y. Katori, H. Motohashi, NRF2 is a key target for prevention of noise-induced hearing loss by reducing oxidative damage of cochlea. Sci Rep. 6, 19329 (2016).

  12. M. Taniguchi, H. Matsuo, S. Shimizu, A. Nakayama, K. Suzuki, N. Hamajima, N. Shinomiya, S. Nishio, S. Kosugi, S. Usami, J. Ito, S. Kitajiri, Carrier frequency of the GJB2 mutations that cause hereditary hearing loss in the Japanese population. J. Hum. Genet. 60, 613-617 (2015).

  13. H. Matsuo, K. Yamamoto, H. Nakaoka, A. Nakayama, M. Sakiyama, T. Chiba, A. Takahashi, T. Nakamura, H. Nakashima, Y. Takada, I. Danjoh, S. Shimizu, J. Abe, Y. Kawamura, S. Terashige, H. Ogata, S. Tatsukawa, G. Yin, R. Okada, E. Morita, M. Naito, A. Tokumasu, H. Onoue, K. Iwaya, T. Ito, T. Takada, K. Inoue, Y. Kato, Y. Nakamura, Y. Sakurai, H. Suzuki, Y. Kanai, T. Hosoya, N. Hamajima, I. Inoue, M. Kubo, K. Ichida, H. Ooyama, T. Shimizu, N. Shinomiya, Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis, 75, 652-659 (2016). (epub ahead of print, on Feb 2, 2015).

  14. T. Takada, K. Ichida, H. Matsuo, A. Nakayama, K. Murakami, Y. Yamanashi, H. Kasuga, N. Shinomiya, H. Suzuki, ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion. Nucleosides Nucleotides Nucleic Acids 33, 275-281 (2014).

  15. M. Sakiyama, H. Matsuo, Y. Takada, T. Nakamura, A. Nakayama, T. Takada, S. I. Kitajiri, K. Wakai, H. Suzuki, N. Shinomiya, Ethnic Differences in ATP-binding Cassette Transporter, Sub-Family G, Member 2 (ABCG2/BCRP): Genotype Combinations and Estimated Functions. Drug Metab Pharmacokinet. 29, 490-492 (2014).

  16. M. Sakiyama, H. Matsuo, S. Shimizu, H. Nakashima, A. Nakayama, T. Chiba, M. Naito, T. Takada, H. Suzuki, N. Hamajima, K. Ichida, T. Shimizu, N. Shinomiya, A common variant of organic anion transporter 4 (OAT4/SLC22A11) gene is associated with renal underexcretion type gout. Drug Metab Pharmacokinet 29, 208-210 (2014).

  17. M. Sakiyama, H. Matsuo, S. Shimizu, T. Chiba, A. Nakayama, Y. Takada, T. Nakamura, T. Takada, E. Morita, M. Naito, K. Wakai, H. Inoue, S. Tatsukawa, J. Sato, K. Shimono, T. Makino, T. Satoh, H. Suzuki, Y. Kanai, N. Hamajima, Y. Sakurai, K. Ichida, T. Shimizu, N. Shinomiya, Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is associated with gout susceptibility. Hum Cell 27, 1-4 (2014).

  18. M. Sakiyama, H. Matsuo, T. Chiba, A. Nakayama, T. Nakamura, S. Shimizu, E. Morita, N. Fukuda, H. Nakashima, Y. Sakurai, K. Ichida, T. Shimizu, N. Shinomiya, Common variants of cGKII/PRKG2 are not associated with gout susceptibility. J Rheumatol 41, 1395-1397 (2014).

  19. A. Nakayama, H. Matsuo, T. Shimizu, Y. Takada, T. Nakamura, S. Shimizu, T. Chiba, M. Sakiyama, M. Naito, E. Morita, K. Ichida, N. Shinomiya, Common variants of a urate-associated gene LRP2 are not associated with gout susceptibility. Rheumatol Int 34, 473-476 (2014).

  20. A. Nakayama, H. Matsuo, H. Nakaoka, T. Nakamura, H. Nakashima, Y. Takada, Y. Oikawa, T. Takada, M. Sakiyama, S. Shimizu, Y. Kawamura, T. Chiba, J. Abe, K. Wakai, S. Kawai, R. Okada, T. Tamura, Y. Shichijo, A. Akashi, H. Suzuki, T. Hosoya, Y. Sakurai, K. Ichida, N. Shinomiya, Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. Sci Rep 4, 5227 (2014).

  21. K. Miyazaki, Y. Morimoto, N. Nishiyama, H. Satoh, M. Tanaka, N. Shinomiya, K. Ito, Preconditioning methods influence tumor property in an orthotopic bladder urothelial carcinoma rat model. Mol Clin Oncol 2, 65-70 (2014).

  22. M. Miyamoto, M. Takano, K. Iwaya, N. Shinomiya, M. Kato, T. Aoyama, N. Sasaki, T. Goto, A. Suzuki, J. Hitrata, K. Furuya, X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary. Br J Cancer 110, 2881-2886 (2014).

  23. H. Matsuo, T. Takada, A. Nakayama, T. Shimizu, M. Sakiyama, S. Shimizu, T. Chiba, H. Nakashima, T. Nakamura, Y. Takada, Y. Sakurai, T. Hosoya, N. Shinomiya, K. Ichida, ABCG2 dysfunction increases the risk of renal overload hyperuricemia. Nucleosides Nucleotides Nucleic Acids 33, 266-274 (2014).

  24. H. Matsuo, A. Nakayama, M. Sakiyama, T. Chiba, S. Shimizu, Y. Kawamura, H. Nakashima, T. Nakamura, Y. Takada, Y. Oikawa, T. Takada, H. Nakaoka, J. Abe, H. Inoue, K. Wakai, S. Kawai, Y. Guang, H. Nakagawa, T. Ito, K. Niwa, K. Yamamoto, Y. Sakurai, H. Suzuki, T. Hosoya, K. Ichida, T. Shimizu, N. Shinomiya, ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep 4, 3755 (2014).

  25. T. Chiba, H. Matsuo, S. Nagamori, A. Nakayama, Y. Kawamura, S. Shimizu, M. Sakiyama, M. Hosoyamada, S. Kawai, R. Okada, N. Hamajima, Y. Kanai, N. Shinomiya, Identification of a hypouricemia patient with SLC2A9 R380W, a pathogenic mutation for renal hypouricemia type 2. Nucleosides Nucleotides Nucleic Acids 33, 261-265 (2014).

  26. T. Chiba, H. Matsuo, Y. Kawamura, S. Nagamori, T. Nishiyama, L. Wei, A. Nakayama, T. Nakamura, M. Sakiyama, T. Takada, Y. Taketani, S. Suma, M. Naito, T. Oda, H. Kumagai, Y. Moriyama, K. Ichida, T. Shimizu, Y. Kanai, N. Shinomiya, NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function variant decreases the risk of renal underexcretion gout. Arthritis Rheumatol, (2014).

  27. Q. Xie, Y. Su, K. Dykema, J. Johnson, J. Koeman, V. De Giorgi, A. Huang, R. Schlegel, C. Essenburg, L. Kang, K. Iwaya, S. Seki, S. K. Khoo, B. Zhang, F. Buonaguro, F. M. Marincola, K. Furge, G. F. Vande Woude, N. Shinomiya, Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer 4, 247-260 (2013).

  28. M. Tanaka, P. Mroz, T. Dai, L. Huang, Y. Morimoto, M. Kinoshita, Y. Yoshihara, N. Shinomiya, S. Seki, K. Nemoto, M. R. Hamblin, Linezolid and vancomycin decrease the therapeutic effect of methylene blue-photodynamic therapy in a mouse model of MRSA bacterial arthritis. Photochem Photobiol 89, 679-682 (2013).

  29. S. Takeuchi, K. Wada, T. Toyooka, N. Shinomiya, H. Shimazaki, K. Nakanishi, K. Nagatani, N. Otani, H. Osada, Y. Uozumi, H. Matsuo, H. Nawashiro, Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery 72, 33-41; discussion 41 (2013).

  30. N. Shinomiya, M. Minehata, M. Dando, Bioweapons and Dual-Use Research of Concern. Journal of Disaster Research 8, 654-666 (2013).

  31. M. Sakiyama, H. Matsuo, S. Shimizu, H. Nakashima, A. Nakayama, T. Chiba, M. Naito, T. Takada, H. Suzuki, N. Hamajima, K. Ichida, T. Shimizu, N. Shinomiya, A Common Variant of Organic Anion Transporter 4 (OAT4/SLC22A11) Gene Is Associated with Renal Underexcretion Type Gout. Drug Metab Pharmacokinet, (2013).

  32. A. Nakayama, H. Matsuo, T. Shimizu, H. Ogata, Y. Takada, H. Nakashima, T. Nakamura, S. Shimizu, T. Chiba, M. Sakiyama, C. Ushiyama, T. Takada, K. Inoue, S. Kawai, A. Hishida, K. Wakai, N. Hamajima, K. Ichida, Y. Sakurai, Y. Kato, T. Shimizu, N. Shinomiya, A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. Hum Cell 26, 133-136 (2013).

  33. M. Minehata, J. Sture, N. Shinomiya, S. Whitby, M. Dando, Promoting Education of Dual-Use Issues for Life Scientists: A Comprehensive Approach. Journal of Disaster Research 8, 674-685 (2013).

  34. M. Minehata, J. Sture, N. Shinomiya, S. Whitby, Implementing biosecurity education: approaches, resources and programmes. Sci Eng Ethics 19, 1473-1486 (2013).

  35. H. Matsuo, K. Ichida, T. Takada, A. Nakayama, H. Nakashima, T. Nakamura, Y. Kawamura, Y. Takada, K. Yamamoto, H. Inoue, Y. Oikawa, M. Naito, A. Hishida, K. Wakai, C. Okada, S. Shimizu, M. Sakiyama, T. Chiba, H. Ogata, K. Niwa, M. Hosoyamada, A. Mori, N. Hamajima, H. Suzuki, Y. Kanai, Y. Sakurai, T. Hosoya, T. Shimizu, N. Shinomiya, Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep 3, 2014 (2013).

  36. M. Tanaka, P. Mroz, T. Dai, L. Huang, Y. Morimoto, M. Kinoshita, Y. Yoshihara, K. Nemoto, N. Shinomiya, S. Seki, M. R. Hamblin, Photodynamic therapy can induce a protective innate immune response against murine bacterial arthritis via neutrophil accumulation. PLoS One 7, e39823 (2012).

  37. M. Tanaka, M. Kinoshita, Y. Yoshihara, N. Shinomiya, S. Seki, K. Nemoto, T. Hirayama, T. Dai, L. Huang, M. R. Hamblin, Y. Morimoto, Optimal photosensitizers for photodynamic therapy of infections should kill bacteria but spare neutrophils. Photochem Photobiol 88, 227-232 (2012).

  38. M. Tanaka, M. Kinoshita, Y. Yoshihara, N. Shinomiya, S. Seki, K. Nemoto, T. Hirayama, T. Dai, L. Huang, M. R. Hamblin, Y. Morimoto, Optimal photosensitizers for photodynamic therapy of infections should kill bacteria but spare neutrophils. Photochem Photobiol 88, 227-232 (2012).

  39. S. Takeuchi, H. Nawashiro, K. Wada, N. Nomura, T. Toyooka, N. Otani, H. Osada, H. Matsuo, N. Shinomiya, L-Leucine induces growth arrest and persistent ERK activation in glioma cells. Amino Acids 43, 717-724 (2012).

  40. J. Sture, M. Minehata, N. Shinomiya, Looking at the formulation of national biosecurity education action plans. Med Confl Surviv 28, 85-97 (2012).

  41. N. Shinomiya, [Infectious diseases: progress in diagnosis and treatment. Topics: I. Infectious diseases in unusual circumstances: 3. The possibility of bioterrorism and its countermeasures]. Nihon Naika Gakkai Zasshi 101, 3103-3113 (2012).

  42. M. Nakashima, M. Kinoshita, H. Nakashima, Y. Habu, H. Miyazaki, S. Shono, S. Hiroi, N. Shinomiya, K. Nakanishi, S. Seki, Pivotal Advance: Characterization of mouse liver phagocytic B cells in innate immunity. J Leukoc Biol 91, 537-546 (2012).

  43. K. Miyazaki, Y. Morimoto, N. Nishiyama, Y. Maekawa, W. Z. Hu, K. I. Nakatate, K. Kaneda, N. Shinomiya, K. Kataoka, A novel homogeneous irradiation fiber probe for whole bladder wall photodynamic therapy. Lasers Surg Med, (2012).

  44. K. Miyazaki, Y. Morimoto, N. Nishiyama, Y. Maekawa, W. Z. Hu, K. Nakatate, K. Kaneda, N. Shinomiya, K. Kataoka, A novel homogeneous irradiation fiber probe for whole bladder wall photodynamic therapy. Lasers Surg Med 44, 413-420 (2012).

  45. K. Ichida, H. Matsuo, T. Takada, A. Nakayama, K. Murakami, T. Shimizu, Y. Yamanashi, H. Kasuga, H. Nakashima, T. Nakamura, Y. Takada, Y. Kawamura, H. Inoue, C. Okada, Y. Utsumi, Y. Ikebuchi, K. Ito, M. Nakamura, Y. Shinohara, M. Hosoyamada, Y. Sakurai, N. Shinomiya, T. Hosoya, H. Suzuki, Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 3, 764 (2012).

  46. T. Toyooka, H. Nawashiro, N. Shinomiya, K. Shima, Down-regulation of glial fibrillary acidic protein and vimentin by RNA interference improves acute urinary dysfunction associated with spinal cord injury in rats. J Neurotrauma 28, 607-618 (2011).

  47. M. Tanaka, M. Kinoshita, Y. Yoshihara, N. Shinomiya, S. Seki, K. Nemoto, M. R. Hamblin, Y. Morimoto, Photodynamic therapy using intra-articular Photofrin for murine MRSA arthritis: biphasic light dose response for neutrophil-mediated antibacterial effect. Lasers Surg Med 43, 221-229 (2011).

  48. S. Takeuchi, H. Nawashiro, K. Wada, N. Nomura, T. Toyooka, N. Otani, H. Osada, H. Matsuo, N. Shinomiya, L: -Leucine induces growth arrest and persistent ERK activation in glioma cells. Amino Acids, (2011).

  49. S. Shono, Y. Habu, M. Nakashima, A. Sato, H. Nakashima, H. Miyazaki, M. Kinoshita, G. Tsumatori, N. Shinomiya, S. Seki, The immunologic outcome of enhanced function of mouse liver lymphocytes and Kupffer cells by high-fat and high-cholesterol diet. Shock 36, 484-493 (2011).

  50. H. Nawashiro, N. Shinomiya, Everolimus and giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 364, 576-577; author reply 577 (2011).

  51. A. Nakayama, H. Matsuo, T. Takada, K. Ichida, T. Nakamura, Y. Ikebuchi, K. Ito, T. Hosoya, Y. Kanai, H. Suzuki, N. Shinomiya, ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans. Nucleosides Nucleotides Nucleic Acids 30, 1091-1097 (2011).

  52. M. Minehata, J. Sture, N. Shinomiya, S. Whitby, Implementing Biosecurity Education: Approaches, Resources and Programmes. Sci Eng Ethics, (2011).

  53. H. Matsuo, T. Takada, K. Ichida, T. Nakamura, A. Nakayama, Y. Takada, C. Okada, Y. Sakurai, T. Hosoya, Y. Kanai, H. Suzuki, N. Shinomiya, Identification of ABCG2 dysfunction as a major factor contributing to gout. Nucleosides Nucleotides Nucleic Acids 30, 1098-1104 (2011).

  54. H. Matsuo, T. Takada, K. Ichida, T. Nakamura, A. Nakayama, H. Suzuki, T. Hosoya, N. Shinomiya, ABCG2/BCRP dysfunction as a major cause of gout. Nucleosides Nucleotides Nucleic Acids 30, 1117-1128 (2011).

  55. M. Kinoshita, H. Miyazaki, S. Ono, A. Inatsu, H. Nakashima, H. Tsujimoto, N. Shinomiya, D. Saitoh, S. Seki, Enhancement of Neutrophil Function by Interleukin-18 Therapy Protects Burn-Injured Mice from Methicillin-Resistant Staphylococcus aureus. Infect Immun 79, 2670-2680 (2011).

  56. Y. Kawamura, H. Matsuo, T. Chiba, S. Nagamori, A. Nakayama, H. Inoue, Y. Utsumi, T. Oda, J. Nishiyama, Y. Kanai, N. Shinomiya, Pathogenic GLUT9 mutations causing renal hypouricemia type 2 (RHUC2). Nucleosides Nucleotides Nucleic Acids 30, 1105-1111 (2011).

  57. M. Fujita, H. Sato, K. Kaku, S. Tokuno, Y. Kanatani, S. Suzuki, N. Shinomiya, Airport quarantine inspection, follow-up observation, and the prevention of pandemic influenza. Aviat Space Environ Med 82, 782-789 (2011).

  58. T. Yamamoto, M. Kinoshita, N. Shinomiya, S. Hiroi, H. Sugasawa, Y. Matsushita, T. Majima, D. Saitoh, S. Seki, Pretreatment with ascorbic acid prevents lethal gastrointestinal syndrome in mice receiving a massive amount of radiation. J Radiat Res (Tokyo) 51, 145-156 (2010).

  59. S. Watanabe, H. Matsuo, Y. Kobayashi, Y. Satoh, M. Fujita, A. Nakayama, Y. Aizawa, N. Shinomiya, S. Suzuki, Transient degradation of myelin basic protein in the rat hippocampus following acute carbon monoxide poisoning. Neurosci Res 68, 232-240 (2010).

  60. M. Tanaka, M. Kinoshita, Y. Yoshihara, N. Shinomiya, S. Seki, K. Nemoto, Y. Morimoto, Influence of intra-articular neutrophils on the effects of photodynamic therapy for murine MRSA arthritis. Photochem Photobiol 86, 403-409 (2010).

  61. A. Hirao, S. Sato, D. Saitoh, N. Shinomiya, H. Ashida, M. Obara, In vivo photoacoustic monitoring of photosensitizer distribution in burned skin for antibacterial photodynamic therapy. Photochem Photobiol 86, 426-430 (2010).

  62. H. Matsuo, T. Takada, K. Ichida, T. Nakamura, A. Nakayama, Y. Ikebuchi, K. Ito, Y. Kusanagi, T. Chiba, S. Tadokoro, Y. Takada, Y. Oikawa, H. Inoue, K. Suzuki, R. Okada, J. Nishiyama, H. Domoto, S. Watanabe, M. Fujita, Y. Morimoto, M. Naito, K. Nishio, A. Hishida, K. Wakai, Y. Asai, K. Niwa, K. Kamakura, S. Nonoyama, Y. Sakurai, T. Hosoya, Y. Kanai, H. Suzuki, N. Hamajima, N. Shinomiya, Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 1, 5ra11 (2009).

  63. A. Matsumoto, H. Tsujimoto, S. Ono, M. Kinoshita, Y. Habu, T. Kawabata, N. Shinomiya, S. Seki, Loss of hepatic B cells following lipopolysaccharide injection and polymicrobial sepsis. J Gastroenterol Hepatol 24, 262-269 (2009).

  64. T. Toyooka, H. Nawashiro, N. Shinomiya, A. Yano, H. Ooigawa, A. Ohsumi, Y. Uozumi, Y. Yanagawa, H. Matsuo, K. Shima, Up-regulation of L type amino acid transporter 1 after spinal cord injury in rats. Acta Neurochir Suppl 102, 385-388 (2008).

  65. K. Sato, N. Shinomiya, [Identification of four species of human malaria parasites by fast PCR]. Rinsho Byori 56, 657-661 (2008).

  66. H. Nakashima, M. Kinoshita, M. Nakashima, Y. Habu, S. Shono, T. Uchida, N. Shinomiya, S. Seki, Superoxide produced by Kupffer cells is an essential effector in concanavalin A-induced hepatitis in mice. Hepatology 48, 1979-1988 (2008).

  67. H. Matsuo, T. Chiba, S. Nagamori, A. Nakayama, H. Domoto, K. Phetdee, P. Wiriyasermkul, Y. Kikuchi, T. Oda, J. Nishiyama, T. Nakamura, Y. Morimoto, K. Kamakura, Y. Sakurai, S. Nonoyama, Y. Kanai, N. Shinomiya, Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83, 744-751 (2008).

  68. T. Kawabata, M. Kinoshita, A. Inatsu, Y. Habu, H. Nakashima, N. Shinomiya, S. Seki, Functional alterations of liver innate immunity of mice with aging in response to CpG-oligodeoxynucleotide. Hepatology 48, 1586-1597 (2008).

  69. K. Chochi, T. Ichikura, M. Kinoshita, T. Majima, N. Shinomiya, H. Tsujimoto, T. Kawabata, H. Sugasawa, S. Ono, S. Seki, H. Mochizuki, Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res 14, 2909-2917 (2008).

  70. T. Uchida, M. Kinoshita, M. Fukasawa, Y. Habu, N. Shinomiya, S. Seki, IL-18 time-dependently modulates Th1/Th2 cytokine production by ligand-activated NKT cells. Eur J Immunol 37, 966-977 (2007).

  71. E. Takahashi, N. Kuranaga, K. Satoh, Y. Habu, N. Shinomiya, T. Asano, S. Seki, M. Hayakawa, Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells. Scand J Immunol 65, 126-138 (2007).

  72. K. Sawada, A. R. Radjabi, N. Shinomiya, E. Kistner, H. Kenny, A. R. Becker, M. A. Turkyilmaz, R. Salgia, S. D. Yamada, G. F. Vande Woude, M. S. Tretiakova, E. Lengyel, c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67, 1670-1679 (2007).

  73. Y. Habu, N. Shinomiya, M. Kinoshita, A. Matsumoto, T. Kawabata, S. Seki, Mice deficient in Vbeta8+NKT cells are resistant to experimental hepatitis but are partially susceptible to generalised Shwartzman reaction. Clin Exp Med 7, 30-38 (2007).

  74. H. Nawashiro, N. Otani, N. Shinomiya, S. Fukui, H. Ooigawa, K. Shima, H. Matsuo, Y. Kanai, H. Endou, L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119, 484-492 (2006).

  75. H. Nakashima, T. Inui, Y. Habu, M. Kinoshita, S. Nagao, A. Kawaguchi, S. Miura, N. Shinomiya, H. Yagita, S. Seki, Activation of mouse natural killer T cells accelerates liver regeneration after partial hepatectomy. Gastroenterology 131, 1573-1583 (2006).

  76. H. Murakami, N. Shinomiya, T. Kikuchi, Y. Yoshihara, K. Nemoto, Upregulated expression of inducible nitric oxide synthase plays a key role in early apoptosis after anterior cruciate ligament injury. J Orthop Res 24, 1521-1534 (2006).

  77. A. Motegi, M. Kinoshita, K. Sato, N. Shinomiya, S. Ono, S. Nonoyama, H. Hiraide, S. Seki, An in vitro Shwartzman reaction-like response is augmented age-dependently in human peripheral blood mononuclear cells. J Leukoc Biol 79, 463-472 (2006).

  78. A. Matsumoto, M. Kinoshita, S. Ono, H. Tsujimoto, T. Majima, Y. Habu, N. Shinomiya, S. Seki, Cooperative IFN-gamma production of mouse liver B cells and natural killer cells stimulated with lipopolysaccharide. J Hepatol 45, 290-298 (2006).

  79. N. Kuranaga, M. Kinoshita, T. Kawabata, Y. Habu, N. Shinomiya, S. Seki, Interleukin-18 protects splenectomized mice from lethal Streptococcus pneumoniae sepsis independent of interferon-gamma by inducing IgM production. J Infect Dis 194, 993-1002 (2006).

  80. M. Kinoshita, N. Shinomiya, S. Ono, H. Tsujimoto, T. Kawabata, A. Matsumoto, H. Hiraide, S. Seki, Restoration of natural IgM production from liver B cells by exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas aeruginosa. J Immunol 177, 4627-4635 (2006).

  81. M. Kinoshita, N. Kuranaga, A. Matsumoto, S. Ono, N. Shinomiya, H. Hiraide, S. Seki, Multiple interleukin-18 injections promote both mouse Th1 and Th2 responses after sublethal Escherichia coli infection. Clin Exp Immunol 143, 41-49 (2006).